Alteogen Licenses Subcutaneous Platform to Undisclosed Global Pharma Company in Deal Worth Up to $365 Million

Alteogen has entered an exclusive license agreement granting an undisclosed global pharmaceutical company worldwide rights to develop and commercialize a subcutaneous (SC) biologic product using ALT-B4 (berahyaluronidase alfa), the company's proprietary hyaluronidase enabled by its Hybrozyme platform. Alteogen is eligible to receive up to $365 million, including an upfront payment plus development, regulatory, and sales milestones, along with royalties on net sales after commercialization.¹

"We are pleased to enter into this license agreement with a global leader with a long-standing commitment to advancing innovative therapies for patients with serious unmet medical needs," said Tae-Yon Chun, PhD, CEO of Alteogen, in a company press release.¹ "We will continue to accelerate the growth of our platform technology through strategic global partnerships."

Alteogen did not disclose the identity of its partner or the specific biologic product covered by the agreement, nor a breakdown of the milestone payments.

What broader industry trend does this deal reflect?

The deal is the latest in a string of announcements over the past several months reflecting a broader industry push to convert intravenously administered biologics into more convenient SC formulations. In January 2026, Alteogen licensed ALT-B4 to Tesaro, a GSK subsidiary, for a subcutaneous formulation of the programmed cell death protein 1 inhibitor dostarlimab, receiving a $20 million upfront payment and eligibility for up to $265 million in additional milestones.² In July 2026, Halozyme Therapeutics entered a global collaboration and license agreement with Incyte to develop SC formulations of INCA033989, a monoclonal antibody in development for myeloproliferative neoplasms, using Halozyme's ENHANZE recombinant hyaluronidase technology.³ That same month, Johnson & Johnson's Rybrevant Faspro, a SC epidermal growth factor receptor- and mesenchymal-epithelial transition-targeted therapy that also uses Halozyme's ENHANZE platform, received FDA priority review to expand its use from lung cancer into head and neck cancer.⁴ SC formulations are generally intended to shorten administration time relative to intravenous infusion, reduce the need for infusion-center visits, and in some cases extend a product's competitive life as patents on the original intravenous formulation near expiration.

How does ALT-B4 work?

ALT-B4 is a recombinant human hyaluronidase that temporarily depolymerizes hyaluronan in the extracellular matrix, facilitating rapid dispersion and absorption of co-administered therapeutics and enabling large-volume SC delivery of drugs typically given by IV infusion.¹

What are the limitations?

Because Alteogen has not disclosed the partner, product, or specific milestone structure, the deal's clinical and commercial significance cannot yet be independently assessed. Further details are expected as development progresses or if the partner discloses the collaboration.

References

1. Alteogen. Alteogen announces exclusive license agreement with a global pharmaceutical company for the development and commercialization of a Hybrozyme-enabled subcutaneous biologic product. News release. Published August 5, 2026. Accessed August 5, 2026. https://www.prnewswire.com/news-releases/alteogen-announces-exclusive-license-agreement-with-a-global-pharmaceutical-company-for-the-development-and-commercialization-of-a-hybrozyme-enabled-subcutaneous-biologic-product-302843463.html
2. Alteogen. Alteogen announces exclusive license agreement with Tesaro, a subsidiary of GSK, for the development of a subcutaneous formulation of dostarlimab enabled by Hybrozyme technology. News Release. Published January 20, 2026. Accessed August 5, 2026. https://www.prnewswire.com/news-releases/alteogen-announces-exclusive-license-agreement-with-tesaro-a-subsidiary-of-gsk-for-the-development-of-a-subcutaneous-formulation-of-dostarlimab-enabled-by-hybrozyme-technology-302665173.html
3. Halozyme Therapeutics. Halozyme announces global collaboration and license agreement with Incyte to support the development of subcutaneous formulations of INCA033989 using its Enhanze technology. Press release. Published July 20, 2026. Accessed August 5, 2026. https://ir.halozyme.com/news/news-details/2026/Halozyme-Announces-Global-Collaboration-and-License-Agreement-with-Incyte-to-Support-the-Development-of-Subcutaneous-Formulations-of-INCA033989-Using-its-ENHANZE-Technology/default.aspx?_gl=1*bqspbq*_up*MQ..*_ga*MTIwNDg2NTMxMC4xNzg0NTUzMzI1*_ga_T1NMWLFHFZ*czE3ODQ1NTMzMjQkbzEkZzAkdDE3ODQ1NTMzMjQkajYwJGwwJGgw*_ga_VXX5W0L85Q*czE3ODQ1NTMzMjUkbzEkZzAkdDE3ODQ1NTMzMjUkajYwJGwwJGgw
4. Johnson & Johnson. Johnson & Johnson's Rybrevant Faspro (amivantamab and hyaluronidase-ipuj) receives US FDA priority review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer. Press release. Published July 30, 2026. Accessed August 5, 2026. https://www.jnj.com/media-center/press-releases/johnson-johnsons-rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-receives-u-s-fda-priority-review-as-potential-first-in-class-egfr-and-met-targeted-subcutaneous-treatment-for-advanced-head-and-neck-cancer